Novartis Ag (NVSEF) Other Non Operating Income (2009 - 2026)

Novartis Ag has disclosed Other Non Operating Income across 16 years of filings, most recently posting -$50.0 million for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at -$50.0 million, down 394.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$203.0 million (down 234.44% YoY), and the FY2025 annual result was -$136.0 million, down 197.14% from the prior year.
• Other Non Operating Income came in at -$50.0 million for Q1 2026 at Novartis Ag, up from -$92.0 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $104.0 million in Q1 2023 to a low of -$92.0 million in Q4 2025.
• The 5-year median for Other Non Operating Income is $17.0 million (2025), against an average of $12.2 million.
• Across the five-year window, Other Non Operating Income soared 431.25% in 2023 and slumped 394.12% in 2026, its largest moves.
• Novartis Ag's Other Non Operating Income stood at $24.0 million in 2022, then declined by 25.0% to $18.0 million in 2023, then soared by 83.33% to $33.0 million in 2024, then slumped by 378.79% to -$92.0 million in 2025, then soared by 45.65% to -$50.0 million in 2026.
• The last three Other Non Operating Income figures came in at -$50.0 million (Q1 2026), -$92.0 million (Q4 2025), and -$20.0 million (Q3 2025), per Business Quant data.